Delivery Order SPE2DB24D1007-SPE2DB25FB5RA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,629.66 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on May 29, 2025, with completion scheduled for May 30, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award through open procurement. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $1,365.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector pharmaceutical supplies. This non-set-aside award, issued on August 25, 2025, with completion targeted for August 26, 2025, represents a single delivery transaction under AmerisourceBergen's existing DLA contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector supplies on May 8, 2025, with completion scheduled for May 9, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen's Corporate Office...
- The Defense Logistics Agency awarded a $1,167.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 ml auto-injector units, with a completion date of September 15, 2025. This non-set-aside competitive award represents a single delivery order transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order worth $1,472.66 to AmerisourceBergen Drug Corporation's Corporate Office division. The order is for 4565470089 XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which allows the agency to efficiently procure a comprehensive range of medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,238.22 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies, with an ultimate completion date of September 15, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 ml auto-injector units, valued at $2,353.38. This was a competitively awarded, firm fixed-price delivery order with an ultimate completion date of August 5, 2025. The contract contains no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injector supplies, valued at $1,375.14 under a firm fixed-price contract type. The award, issued on July 14, 2025, with a completion date of July 15, 2025, represents a non-set-aside competitive award. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, valued at $1,865.12 with a firm fixed price contract type. The order was competitively awarded without set-aside provisions and is scheduled for completion by September 4, 2025, with fulfillment based at the vendor's Conshohocken, Pennsylvania location. This delivery order represents a routine pharmaceutical procurement supporting federal medical...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FB5RADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector vials, with a ceiling value of $1,802.45 and a completion date of September 22, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a pharmaceutical supply delivery under DLA's medical procurement operations. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a primary pharmaceutical distributor for federal medical supply needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support Defense Health Agency programs and other federal healthcare systems worldwide. The company's established track record includes delivering numerous pharmaceutical products across multiple therapeutic domains, demonstrating its capability to fulfill federal medical procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 9/19/25 |